Anti-IL-6/IL-6R antibodies
US-9828430-B2 · Nov 28, 2017 · US
Anti-IL-6/IL-6R antibodies and methods of use thereof
US10759862B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10759862-B2 |
| Application number | US-201715823086-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 27, 2017 |
| Priority date | May 13, 2008 |
| Publication date | Sep 1, 2020 |
| Grant date | Sep 1, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of blocking cis or trans IL-6 signaling in a subject, the method comprising administering an antibody that binds to IL-6/IL-6R complex (IL-6Rc), wherein the antibody comprises a V H CDR1 region comprising the amino acid sequence of SEQ ID NO: 15, a V H CDR2 region comprising the amino acid sequence of SEQ ID NO: 33, a V H CDR3 region comprising the amino acid sequence of SEQ ID NO: 36, a V L CDR1 region comprising the amino acid sequence of SEQ ID NO: 24, a V L CDR2 region comprising the amino acid sequence of SEQ ID NO: 25, and a V L CDR3 region comprising the amino acid sequence of SEQ ID NO: 26. 2. The method of claim 1 , wherein said subject is a human. 3. The method of claim 2 , wherein said antibody also binds the IL-6R. 4. The method of claim 2 , wherein said antibody is an IgG isotype. 5. The method of claim 2 , wherein said antibody is an IgG1 isotype. 6. The method of claim 1 , wherein said subject has renal cell carcinoma (RCC), plasma cell leukemia, lymphoma, B-lymphoproliferative disorder (BLPD), multiple myeloma, prostate cancer, or Kaposi's sarcoma.
Assignees
Inventors
Classifications
Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title
Antiasthmatics · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
IL-6 · CPC title
Drugs for disorders of the nervous system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10759862B2 cover?
- This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
- Who is the assignee on this patent?
- Novimmune Sa
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2866. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).